January 22nd, 2026
Exposing cells to the Yamanaka transcription factors for a short period of time can produce rejuvenation of nuclear DNA structure, epigenetic regulation of that structure, and cell function. Cells in aged tissues become functionally younger following this partial reprogramming, expressing genes in the same way that younger cells do. Initial efforts to build treatments based on this finding have focused on gene therapy approaches, but gene therapy technologies come attached to thorny delivery issues. It remains somewhere between very difficult and impossible to deliver gene therapies to many of the tissues in the body, or to deliver systemically and evenly throughout the body.
Small molecule drugs, on the other hand, can be much better at achieving body-wide distribution of effects. If looking to the near future of the reprogramming field and its efforts to produce rejuvenation therapies, it seems likely that small molecule approaches to reprogramming will give rise to rejuvenation therapies that can affect the whole body well in advance of the development of any effective solutions for the long-standing delivery challenges associated with gene therapies. That said, the present small molecule combinations tested in animal studies still need a fair amount of work in order to produce an outcome acceptable to regulators. The discovery and optimization of entirely new classes of small molecule may be needed.
